Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:20:37 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:ASLN from 2023-04-27 to 2024-04-26 - 29 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
2024-04-22 08:45U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
2024-04-19 17:10U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
2024-04-12 08:00U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-03-27 08:07U:ASLNNews ReleaseAslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
2024-03-12 14:35U:ASLNNews ReleaseASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
2024-03-11 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
2024-03-06 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
2024-02-29 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
2024-01-08 06:45U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
2024-01-02 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Participation in January Investor Conferences
2023-12-12 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
2023-11-20 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
2023-11-03 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
2023-10-27 08:00U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-24 08:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
2023-10-18 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
2023-10-13 09:30U:ASLNNews ReleaseASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
2023-09-22 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
2023-09-07 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-11 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-06 07:55U:ASLNNews ReleaseEblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
2023-07-05 16:30U:ASLNNews ReleaseASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
2023-06-23 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab ¢ € ™s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
2023-06-22 07:30U:ASLNNews ReleaseASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
2023-06-01 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2023-05-18 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
2023-05-15 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
2023-04-28 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update